EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer

P Konstantinopoulos; A González-Martín; F Cruz; M Friedlander; R Glasspool; D Lorusso; C Marth; B Monk; J-W Kim; D Alsadius; V Pretre; Y Han; U Matulonis

doi:10.1136/ijgc-2021-IGCS.350

Article info

E-Posters

E-Poster Viewing

EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer

Free

Authors

P Konstantinopoulos Dana-Farber Cancer Institute, Medical Oncology, Boston, USA PubMed articles Google scholar articles
A González-Martín Clínica Universidad de Navarra, Department of Medical Oncology, Madrid, Spain PubMed articles Google scholar articles
F Cruz Instituto Brasileiro de Controle do Câncer, Clinical Research Center, Sao Paolo, Brazil PubMed articles Google scholar articles
M Friedlander University of New South Wales, Medical Oncology, Sydney, Australia PubMed articles Google scholar articles
R Glasspool Beatson West of Scotland Cancer Centre and University of Glasgow, Clinical Trials Unit, Glasgow, UK PubMed articles Google scholar articles
D Lorusso Fondazione Policlinico Universitario A Gemelli IRCCS, Gynaecology Oncology Unit, Milano, Italy PubMed articles Google scholar articles
C Marth Medizinische Universität Innsbruck, Department of Obstetrics and Gynecology, Innsbruck, Austria PubMed articles Google scholar articles
B Monk University of Arizona, College of Medicine, Phoenix, USA PubMed articles Google scholar articles
J-W Kim Seoul National University, Obstetrics and Gynecology, Seoul, Korea, Republic of PubMed articles Google scholar articles
D Alsadius Novartis Pharmaceuticals Corporation, Global Medical Affairs, Oncology, East Hanover, USA PubMed articles Google scholar articles
V Pretre Novartis Pharmaceuticals Corporation, Global Medical Affairs, Oncology, East Hanover, USA PubMed articles Google scholar articles
Y Han Novartis Pharmaceuticals Corporation, Global Medical Affairs, Oncology, East Hanover, USA PubMed articles Google scholar articles
U Matulonis Dana-Farber Cancer Institute, Medical Oncology, Boston, USA PubMed articles Google scholar articles

Citation

Konstantinopoulos P, González-Martín A, Cruz F, et al

International Journal of Gynecologic Cancer 2021;31:A139-A140.

Publication history

First published November 1, 2021.

Online issue publication

January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password